ArticleCancer discovery2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Open access · hybridAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 2 pooled it
12.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).Breast (Edinburgh, Scotland) · 2024Guideline
- Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2023Pooled it
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.British journal of cancer · 2026Trial
- Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.Nature communications · 2024Trial
- CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nature cancer · 2023Trial
- Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).Breast cancer research : BCR · 2023Trial
- Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.Breast cancer research and treatment · 2022Trial
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.The Journal of clinical investigation · 2026Review
- Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations.NPJ breast cancer · 2026Article
- Genome-Wide Analysis of Alternative Splicing Identifies a Prognostic Signature in ER-Positive Breast Cancer.Genes · 2026Article
- Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survival.Research square · 2026Article
- Article
- Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.Nature communications · 2026Article
- Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.NPJ breast cancer · 2026Review
- Associations of selected atypical non-neuroendocrine cancers with multiple endocrine neoplasia type 1.Journal of the Endocrine Society · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 15 countries.
Philippe AftimosInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Mafalda OliveiraMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0001-9152-8799
Alexandre IrrthumBreast International Group, Brussels, Belgium.
Debora FumagalliBreast International Group, Brussels, Belgium.ORCID 0000-0002-0649-1942
Christos SotiriouInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-5745-9977
Einav Nili Gal-YamSheba Medical Center, Ramat Gan, Israel.
Mark E RobsonMemorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3109-1692
Justin NdozengInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Angelo Di LeoHospital of Prato, Prato, Italy.ORCID 0000-0002-3665-9056
Eva M CiruelosUniversity Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0002-2796-1042
Evandro de AzambujaInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0001-9501-4509
Giuseppe VialeIEO, Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy.
Elsemieke D ScheepersFrontier Science Scotland, Scotland, United Kingdom.
Giuseppe CuriglianoIEO, Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy.ORCID 0000-0003-1781-2518
Judith M BlissThe Institute of Cancer Research, London, United Kingdom.
Jorge S Reis-FilhoHospital of Prato, Prato, Italy.
Marco ColleoniIEO, Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy.ORCID 0000-0002-5743-3013
Marija BalicMedical University of Graz, Graz, Austria.ORCID 0000-0001-9482-9191
Fatima CardosoBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Joan AlbanellHospital del Mar - CIBERONC; IMIM, Barcelona; Pompeu Fabra University, Barcelona, Spain.ORCID 0000-0003-1239-4580
Caroline DuhemCentre Hospitalier Luxembourg, Luxembourg City, Luxembourg.
Sandrine MarreaudEORTC, Brussels, Belgium.
Dario RomagnoliSheba Medical Center, Ramat Gan, Israel.ORCID 0000-0002-2465-2463
Beatriz RojasCIOCC (Centro Integral Oncologico "Clara Campal"), Madrid, Spain.
Andrea GombosInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Hans WildiersUZ Leuven, Leuven, Belgium.ORCID 0000-0001-8990-7837
Angel Guerrero-ZotanoInstituto Valenciano de Oncología, Valencia, Spain.ORCID 0000-0003-0318-9120
Peter HallUniversity of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.ORCID 0000-0001-6015-7841
Andrea BonettiDepartment of Oncology AZIENDA ULSS 9 Verona, Verona, Italy.ORCID 0000-0003-2329-6628
Karolina Fs LarssonSahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0003-2347-3591
Martina DegiorgisCentre Hospitalier Luxembourg, Luxembourg City, Luxembourg.
Silvia KhodaverdiSana Klinikum Offenbach, Klinik für Gynaekologie und Geburtshilfe, Offenbach, Germany.
Richard GreilParacelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria.
Ásgerdur SverrisdóttirLandspitali University Hospital, Reykjavik, Iceland.
Marta PaoliSheba Medical Center, Ramat Gan, Israel.
Ethel SeyllInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Sibylle LoiblGerman Breast Group, Neu-Isenburg, Germany.
Barbro LinderholmSahlgrenska University Hospital, Gothenburg, Sweden.
Gabriele ZoppoliUniversità degli Studi di Genova and IRCCS Ospedale Policlinico San Martino, San Martino, Italy.
Nancy E DavidsonFred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.
Oskar Th JohannssonIBCG, Reykjavik, Iceland.
Philippe L BedardPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.ORCID 0000-0002-6771-2999
Sherene LoiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-6137-9171
Susan KnoxEuropa Donna- The European Breast Cancer Coalition, Milan, Italy.
David A CameronUniversity of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.
Nadia HarbeckBreast Center, LMU University Hospital, Munich, Germany, and West German Study Group, Moenchengladbach, Germany.ORCID 0000-0002-9744-7372
Maite Lasa MontoyaBreast International Group, Brussels, Belgium.
Mariana BrandãoInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-1653-3544
Andrea VingianiFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-9827-3976
Carmela CaballeroBreast International Group, Brussels, Belgium.
Florentine S HilbersBreast International Group, Brussels, Belgium.ORCID 0000-0002-6764-3102
Lucy R YatesWellcome Trust Sanger Institute, London, United Kingdom.
Matteo BenelliHospital of Prato, Prato, Italy.ORCID 0000-0003-1227-356X
David VenetInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0001-9038-5271
Martine J PiccartInstitut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium. martine.piccart@bordet.be.ORCID 0000-0001-9068-8504
Institut Jules Bordet · BEBreast International Group · BEEuropean Institute of Oncology · ITHospital of Prato · ITIsrael Medical Association · ILCentre Hospitalier de Luxembourg · LUEdinburgh Cancer Research · GBSahlgrenska University Hospital · SECentro Oncológico de Galicia · ESChampalimaud Foundation · PTDeutsches Archäologisches Institut, Zentrale · DEEuropa Donna · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITFred Hutch Cancer Center · USFrontier Agriculture (United Kingdom) · GBFundación Instituto Valenciano de Oncología · ESGerman Breast group · DEHebron University · PSIneos (Belgium) · BEInstitute of Cancer Research · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCancer Research UK 25351NCI NIH HHS P30 CA008748
Abstract
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for
Indexed as
Breast NeoplasmsBiomarkers, TumorCell Cycle ProteinsEarly Detection of CancerFemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMutationNeoplasm Recurrence, LocalProto-Oncogene ProteinsTranscriptomeBiomarkers, TumorCell Cycle ProteinsMDM4 protein, humanProto-Oncogene Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.